SCHEMBL8220132

SCHEMBL8220132

O=CC(=O)N1CCCC[C@H]1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.45
REN P00797 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7505332 1.00 ACE (0.45) ACEREN
SCHEMBL27547709 0.94 ACE (0.50) ACEREN
SCHEMBL27547710 0.94 ACE (0.50) ACEREN
SCHEMBL4863667 0.87 ACE (0.44) ACEREN
SCHEMBL17652360 0.87 ACE (0.44) ACEREN
SCHEMBL18616806 0.87 ACE (0.44) ACEREN
SCHEMBL18616038 0.81 ACE (0.49) ACEREN
SCHEMBL4866241 0.81 ACE (0.49) ACEREN
SCHEMBL4859280 0.81 ACE (0.49) ACEREN
SCHEMBL15482646 0.80 ACE (0.43) ACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9827315-B2 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives THEMIS MEDICARE LIMITED (IN) 2017-11-28 US disclosed
WO-2008021981-A2 LOCAL TREATMENT OF EPIDERMAL AND DERMAL HYPERPROLIFERATIVE LESIONS NEXGENIX PHARMACEUTICALS, LLC. (US) 2008-02-21 WO disclosed